Skip to content

2HIT-Medulloblastoma Oncology Active

New therapy for pediatric patients with group 3 medulloblastoma (MB G3)

Oncoheroes Biosciences’ first drug discovery project aims to develop a more effective and less toxic therapy for medulloblastoma (MB), the most prevalent brain tumor and one of the most aggressive in children. Among the subtypes, Group 3 MB has the worst prognosis, especially if it is associated with MYC gene amplification, with only 20% of patients surviving 5 years after diagnosis.

Eva Mendez
Project Manager
ONCOHEROES BIOSCIENCES. With the collaboration of: IQS · Xenopat · Nostrum Biodiscovery · National Foundation For Cancer Research

DO YOU HAVE AN INNOVATIVE PROJECT?

We are looking for you!

Send Project